Home › Funds › Siren, L.L.C. › ELVN
Siren, L.L.C. position in ELVN
Enliven Therapeutics, Inc. · Health Care
Siren, L.L.C. reported holding 1,475,163 shares of ELVN (Enliven Therapeutics, Inc.) in its Q3 2026 13F filing — a position valued at US$67.6M, representing 1.61% of its reported portfolio and ranking #18 among its reported holdings. Siren, L.L.C. has disclosed ELVN holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s ELVN position evolved
Siren, L.L.C. first disclosed a stake in ELVN in Q1 2026 at 746,226 shares (US$29.3M). The position peaked in Q2 2026 at 1,774,411 shares, worth US$90.1M. Across 3 filings, Siren, L.L.C. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,475,163 shares valued at US$67.6M — a reduction of -299,248 shares quarter over quarter.. Notable position changes include a 138% increase in Q2 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 746.23K | $29.25M | New |
| Q2 2026 | 1.77M | $90.05M | Add |
| Q3 2026 | 1.48M | $67.62M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (Enliven Therapeutics, Inc.) is a Health Care company. 67 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $343.91M · Q2 2026
- Polar Capital Holdings Plc 6.43M sh · $326.35M · Q2 2026
- Vestal Point Capital, LP 4.00M sh · $203.00M · Q2 2026
- Commodore Capital LP 3.27M sh · $166.21M · Q2 2026
- Fairmount Funds Management LLC 1.86M sh · $94.17M · Q2 2026
- Bellevue Group AG 1.49M sh · $75.62M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $69.06M · Q2 2026
- Novo Holdings A/S 1.00M sh · $50.75M · Q2 2026
- First Turn Management, LLC 954.36K sh · $48.43M · Q2 2026
- SAMLYN CAPITAL, LLC 912.64K sh · $46.32M · Q2 2026
- BAKER BROS. ADVISORS LP 905.19K sh · $45.94M · Q2 2026
- Tri Locum Partners LP 866.72K sh · $43.99M · Q2 2026
More on Siren, L.L.C.
FAQ
How long has Siren, L.L.C. held ELVN?
Siren, L.L.C. has disclosed ELVN holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Siren, L.L.C.'s current position in ELVN?
As of Q3 2026, Siren, L.L.C. holds 1.48M shares of ELVN (Enliven Therapeutics, Inc.), valued at $67.62M, representing 1.61% of its reported portfolio and ranking #18.
Has Siren, L.L.C. been buying or selling ELVN?
In the latest 13F filing (Q3 2026), Siren, L.L.C. reduced its position in ELVN. The position peaked in Q2 2026 at 1.77M shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 67 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.